RECRUITING

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The objective of this study is to examine critical aspects of radiation exposure, dose delivery, and systemic yttrium-90 (Y90) exposure related to the infusion of Y90 microspheres for treatment of hepatocellular carcinoma (HCC) and other metastatic liver disease.

Official Title

Y90 Radioembolization Dose Delivery and Radiation Exposure Assessment

Quick Facts

Study Start:2018-06-19
Study Completion:2019-12-31
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT03686709

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * All patients undergoing Y90 radioembolization therapy with SIR-Spheres or TheraSpheres are eligible to participate in this study
  2. * Must be able to schedule and tolerate additional PET/CT imaging following therapy
  3. * Must be able to tolerate additional blood draws before, during, and after the radioembolization therapy procedure.
  1. * Patients that are not candidates for Y90 radioembolization therapy
  2. * Patients that cannot tolerate additional imaging procedures following therapy
  3. * Patients that cannot tolerate the additional blood draws required for this study
  4. * Patients whose schedule does not allow them to remain at the hospital for the additional PET/CT imaging study

Contacts and Locations

Study Contact

Dustin Osborne, PhD
CONTACT
8653058264
dosborne@utmck.edu
Shelley Acuff
CONTACT
8653056312
sacuff@utmck.edu

Principal Investigator

Dustin Osborne, PhD
PRINCIPAL_INVESTIGATOR
University of Tennessee
Christopher Stephens, MD
PRINCIPAL_INVESTIGATOR
University of Tennessee

Study Locations (Sites)

University of Tennessee Medical Center
Knoxville, Tennessee, 37920
United States

Collaborators and Investigators

Sponsor: University of Tennessee

  • Dustin Osborne, PhD, PRINCIPAL_INVESTIGATOR, University of Tennessee
  • Christopher Stephens, MD, PRINCIPAL_INVESTIGATOR, University of Tennessee

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2018-06-19
Study Completion Date2019-12-31

Study Record Updates

Study Start Date2018-06-19
Study Completion Date2019-12-31

Terms related to this study

Additional Relevant MeSH Terms

  • Hepatocellular Carcinoma
  • Radiation Exposure